Literature DB >> 30348676

Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with Nf1 Knockout in Boundary Cap Cells.

Katarzyna J Radomska1, Fanny Coulpier1, Aurelie Gresset1, Alain Schmitt2, Amal Debbiche1, Sophie Lemoine3, Pierre Wolkenstein4, Jean-Michel Vallat5, Patrick Charnay6, Piotr Topilko6.   

Abstract

Patients carrying an inactive NF1 allele develop tumors of Schwann cell origin called neurofibromas (NF). Genetically engineered mouse models have significantly enriched our understanding of plexiform forms of NFs (pNF). However, this has not been the case for cutaneous neurofibromas (cNF), observed in all NF1 patients, as no previous model recapitulates their development. Here, we show that conditional Nf1 inactivation in Prss56-positive boundary cap cells leads to bona fide pNFs and cNFs. This work identifies subepidermal glia as a likely candidate for the cellular origin of cNFs and provides insights on disease mechanisms, revealing a long, multistep pathologic process in which inflammation-related signals play a pivotal role. This new mouse model is an important asset for future clinical and therapeutic investigations of NF1-associated neurofibromas. SIGNIFICANCE: Patients affected by NF1 develop numerous cNFs. We present a mouse model that faithfully recapitulates cNFs, identify a candidate cell type at their origin, analyze the steps involved in their formation, and show that their development is dramatically accelerated by skin injury. These findings have important clinical/therapeutic implications.This article is highlighted in the In This Issue feature, p. 1. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30348676     DOI: 10.1158/2159-8290.CD-18-0156

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  11 in total

1.  NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation.

Authors:  Yanan Yu; Kwangmin Choi; Jianqiang Wu; Paul R Andreassen; Phillip J Dexheimer; Mehdi Keddache; Hilde Brems; Robert J Spinner; Jose A Cancelas; Lisa J Martin; Margaret R Wallace; Eric Legius; Kristine S Vogel; Nancy Ratner
Journal:  Acta Neuropathol       Date:  2019-10-29       Impact factor: 17.088

2.  Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.

Authors:  Daochun Sun; Xuanhua P Xie; Xiyuan Zhang; Zilai Wang; Sameer Farouk Sait; Swathi V Iyer; Yu-Jung Chen; Rebecca Brown; Dan R Laks; Mollie E Chipman; Jack F Shern; Luis F Parada
Journal:  Cell Stem Cell       Date:  2021-05-18       Impact factor: 25.269

3.  The evolution and multi-molecular properties of NF1 cutaneous neurofibromas originating from C-fiber sensory endings and terminal Schwann cells at normal sites of sensory terminations in the skin.

Authors:  Frank L Rice; George Houk; James P Wymer; Sara J C Gosline; Justin Guinney; Jianqiang Wu; Nancy Ratner; Michael P Jankowski; Salvo La Rosa; Marilyn Dockum; James R Storey; Steven L Carroll; Phillip J Albrecht; Vincent M Riccardi
Journal:  PLoS One       Date:  2019-05-20       Impact factor: 3.752

4.  MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK.

Authors:  Youjin Na; Ashley Hall; Kwangmin Choi; Liang Hu; Jonathan Rose; Robert A Coover; Adam Miller; Robert F Hennigan; Eva Dombi; Mi-Ok Kim; Subbaya Subramanian; Nancy Ratner; Jianqiang Wu
Journal:  Oncogene       Date:  2020-12-08       Impact factor: 9.867

Review 5.  Spontaneous and Engineered Large Animal Models of Neurofibromatosis Type 1.

Authors:  Sara H Osum; Adrienne L Watson; David A Largaespada
Journal:  Int J Mol Sci       Date:  2021-02-16       Impact factor: 6.208

Review 6.  Functional Nanoparticles for Enhanced Cancer Therapy.

Authors:  Chenchen Li; Yuqing Li; Guangzhi Li; Song Wu
Journal:  Pharmaceutics       Date:  2022-08-12       Impact factor: 6.525

7.  Characterizing the Metabolic and Immune Landscape of Non-small Cell Lung Cancer Reveals Prognostic Biomarkers Through Omics Data Integration.

Authors:  Fengjiao Wang; Yuanfu Zhang; Yangyang Hao; Xuexin Li; Yue Qi; Mengyu Xin; Qifan Xiao; Peng Wang
Journal:  Front Cell Dev Biol       Date:  2021-07-06

8.  Cdkn2a Loss in a Model of Neurofibroma Demonstrates Stepwise Tumor Progression to Atypical Neurofibroma and MPNST.

Authors:  Katherine E Chaney; Melissa R Perrino; Leah J Kershner; Ami V Patel; Jianqiang Wu; Kwangmin Choi; Tilat A Rizvi; Eva Dombi; Sara Szabo; David A Largaespada; Nancy Ratner
Journal:  Cancer Res       Date:  2020-08-19       Impact factor: 13.312

Review 9.  Translating current basic research into future therapies for neurofibromatosis type 1.

Authors:  Jean-Philippe Brosseau; Chung-Ping Liao; Lu Q Le
Journal:  Br J Cancer       Date:  2020-05-22       Impact factor: 7.640

10.  Humanized neurofibroma model from induced pluripotent stem cells delineates tumor pathogenesis and developmental origins.

Authors:  Juan Mo; Corina Anastasaki; Zhiguo Chen; Tracey Shipman; Jason Papke; Kevin Yin; David H Gutmann; Lu Q Le
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.